Strong growth and stubborn inflation made the bond market’s day particularly uncomfortable. Fresh economic data pushed yields higher even as cooler price readings gave rate-cut hopes a small lift, leaving traders to juggle two different signals.

The backdrop kept shifting as investors weighed growth, inflation, and the Fed’s next move. Keep reading for what drove the session across markets today.

The institutional edge is now accessible.

When you analyze one ticker, this AI processes thousands of intermarket correlations in milliseconds and offers Stock and Options predictions 3 days in advance.

VantagePoint's patented technology forecasts price direction with up to 87.4% proven accuracy by analyzing hidden relationships that move prices before charts reveal them.

In algorithm-driven markets, manual analysis can't compete. 

Imagine the ability to plan entries and exits ahead of the move instead of reacting to it, with less second-guessing.

Download "Your Retirement Playbook: Growing Wealth in the New Markets with A.I.”

*Please note examples are from past data, success stories, and atypical. Trading involves financial risk and is not suitable for all investors. Past results do not guarantee future performance. Trading involves substantial risk of loss and is not suitable for every investor.

The bond market took another hit after revised second-quarter GDP showed the economy grew 2.2%, up from 1.5%, while August core PCE cooled to 3.0% from a revised 3.2%.

That split gave traders plenty to argue about: growth is running hotter, but inflation is easing at the same time. The 10-year yield nevertheless climbed to 5.304%, its highest level since May 2002, as expectations for another Fed hike remained alive.

Oil also moved higher, with Brent near $98.40, adding another inflation headache.

October hike odds slipped toward 39%, showing the market has not completely bought the hawkish case. For now, the economy is making the Fed’s job unusually awkward.

Long-dated Treasurys are still taking the biggest hit from the repricing.

Robinhood is pushing automated investing further into the mainstream with AI agents that can build strategies and execute trades for customers, alongside planned round-the-clock weekend equity trading and new tools to attract more active retail investors.

Hewlett Packard Enterprise is strengthening its AI infrastructure outlook after raising its long-term networking growth forecast and securing a $1.2 billion Vultr order, with AMD-powered server racks headed to U.S. data centers as cloud demand accelerates.

Starbucks is facing renewed pressure over its unresolved union conflict after shareholders sought the return of a board committee overseeing labor relations, arguing that years without a contract could create another risk for Brian Niccol’s turnaround.

Hormel Foods is expanding deeper into value-added chicken through a $1.06 billion acquisition of family-owned processor Brakebush Brothers, adding a business with nearly $1.2 billion in annual sales while strengthening its foodservice relationships and protein portfolio.

Boeing’s 737 MAX fleet will remain in service while it addresses a software issue after U.S. transportation officials said they found no immediate safety concern, while the company develops a permanent update for operators worldwide.

Northrop Grumman lost a major Navy competition to Boeing after the Pentagon selected its rival for the $20 billion F/A-XX development contract, leaving Northrop outside a program designed to replace the F/A-18 and shape carrier aviation for decades.

Moderna’s monthlong rally is facing a valuation warning after Citi downgraded the shares to Sell despite raising its price target, arguing that expectations now assume unrealistic success across several cancer types beyond the company’s promising melanoma vaccine.

Grail is moving closer to a broader commercial opportunity for Galleri as the FDA considers full approval of its multi-cancer blood test, which screens for more than 50 cancers and could unlock Medicare and private-insurance coverage.

This report focuses on a narrow group of stocks identified through a detailed screening process.

Analysts apply a combination of metrics to narrow down potential opportunities.

Past selections have shown strong momentum, but no outcomes are guaranteed.

The newest edition is now open for access.

Get the report now.

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

Brink’s $6.6 billion purchase of NCR Atleos faces a new obstacle after Britain’s competition watchdog warned the ATM combination could weaken competition, giving the companies until October 7 to offer remedies before triggering a deeper Phase 2 investigation.

Fair Isaac faces mounting pressure on its mortgage-scoring franchise after Bank of America cut its rating and halved its price target, citing new federal pricing rules that place VantageScore on more equal footing with FICO.

Armada Acquisition Corp. II [XRPN] $16.40 (+27.13%)

Armada Acquisition jumped as shareholders reached the scheduled vote on Evernorth’s proposed combination, one of the final hurdles before the XRP-focused treasury business can pursue its Nasdaq debut.

The long-awaited deadline finally arrived, giving XRPN a very different trading setup from its sleepy SPAC days. Traders clearly liked having an actual event on the calendar.

United Therapeutics [UTHR] $541.89 (+12.55%)

United Therapeutics caught a bid after a Delaware court ruled that two claims of its’327 patent are valid and infringed by Liquidia.

The ruling directly affects YUTREPIA, Liquidia’s competing inhaled treprostinil treatment for pulmonary hypertension.

With the court now considering the remedy, UTHR suddenly had a fresh legal tailwind behind its respiratory franchise today.

Cardinal Infrastructure Group [CDNL] $30.60 (+11.80%)

Cardinal Infrastructure had another financing-related headline to work with after expanding its credit facility to $550 million, including a new $250 million delayed-draw term loan.

The company says the added capacity can fund acquisitions and related expenses. That gives the acquisition-heavy infrastructure operator more dry powder while it works through a much tougher stretch for the stock.

Liquidia [LQDA] $30.26 (-57.19%)

Liquidia was hit by a Delaware court ruling that two claims of United Therapeutics’ ’327 patent are valid and infringed. The patent covers inhaled treprostinil for pulmonary hypertension associated with interstitial lung disease, directly touching YUTREPIA.

UTHR has asked for injunctive relief that could restrict the drug’s availability, turning a legal dispute into a serious commercial problem.

Scribe Therapeutics [SCTX] $18.41 (-20.08%)

Scribe Therapeutics slid sharply as the newly public biotech continued digesting a rough September.

The company’s latest update highlighted first-in-human dosing for STX-1150, a cholesterol-lowering program, plus more than $25 million in California funding for its pipeline.

The contrast is striking: the business has been adding clinical milestones while the stock has been giving ground.

Eton Pharmaceuticals [ETON] $51.49 (-13.01%)

Eton Pharmaceuticals fell despite adding another commercial product to its rare-disease portfolio this week.

The company announced U.S. commercial availability of IMPAVIDO on Sept. 28, expanding its lineup while retaining exclusive U.S. commercialization rights.

Investors are still looking past the launch toward execution across Eton’s growing portfolio, including products expected to support its longer-term revenue growth.

November 1910. Seven of America's most powerful bankers met in secret on Jekyll Island, Georgia, to design the Federal Reserve.

Since 1913, the dollar has lost over 96% of its purchasing power.

Tan Gera, CFA©, an ex-Wall Street banker, warns CBDCs could be the next step: every transaction tracked, every account programmable.

His free presentation shows investors with $50k+ how decentralized finance offers a way out.

Watch it here

*This content is for educational purposes only. The opinions expressed are from DM Intelligence LLC, doing business as Decentralized Masters, who are not licensed financial advisors or registered investment advisors. The reader acknowledges that DM Intelligence LLC is not responsible for any losses, direct or indirect, resulting from the use of this information, including errors, omissions, or inaccuracies.

*Results are not typical and will vary. Success with digital currencies requires time, effort, and involves substantial risk including total loss of investment. Past performance does not indicate future results. All investments are at your own risk.

*Please click here if you would like to unsubscribe.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.